Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s40256-020-00429-7.pdf
Reference27 articles.
1. Yang N, Shen HM. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci. 2020;16:1724–31.
2. Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjoras M, et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis. 2020;93:268–76.
3. Kadioglu O, Saeed M, Johannes Greten H, Efferth T. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning. Bull World Health Organ. 2020. https://doi.org/10.2471/BLT.20.255943.
4. Rali AS, Sauer AJ. COVID-19 pandemic and cardiovascular disease. US Cardiol Rev. 2020;14:e01.
5. Heijman J, Dobrev D. Pleiotropic actions of amiodarone: still puzzling after half a century. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:571–4.
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lignin and Pluronic-based nanomicelles as promising amiodarone nanocarriers: Synthesis, physical characterization, biological, and in silico evaluations;Industrial Crops and Products;2024-09
2. A Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery;Letters in Drug Design & Discovery;2023-03
3. Dantrolene and ryanodine receptors in COVID‐19: The daunting task and neglected warden;Clinical and Experimental Pharmacology and Physiology;2023-02-28
4. Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges;Drug Repurposing for Emerging Infectious Diseases and Cancer;2023
5. Antiviral activity of amiodarone in SARS-CoV-2 disease;Physiological Research;2022-11-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3